Mykronor (Noradrenaline Tartrate)

Noradrenaline Tartrate, the active ingredient in Mykronor, is a vasopressor presented as an injection solution for intravenous use. It is employed to raise blood pressure in acute hypotensive states and to support circulation during various forms of shock.\n\nGNH India supplies Mykronor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Mykronor acts on the sympathetic vascular pathway to restore perfusion in critical circulatory disorders.\n\nAcute hypotension: rapidly increases systemic vascular resistance to raise blood pressure.\nSeptic shock: supports hemodynamics when fluid resuscitation is insufficient.\nCardiogenic shock: augments cardiac output by improving coronary perfusion.\nCardiac arrest (adjunct): provides vasoconstriction to facilitate coronary and cerebral blood flow during resuscitation.\nAnaphylactic shock (when other agents insufficient): sustains vascular tone when antihistamines and epinephrine are inadequate.

Adverse reactions may arise from excessive vasoconstriction or cardiac stimulation.\n\nCommon Side Effects:\n- Headache: due to rapid rise in blood pressure.\n- Tachycardia: secondary to beta‑1 stimulation.\n- Arrhythmia: ectopic beats or atrial fibrillation.\n- Peripheral ischemia: reduced blood flow to extremities.\n- Nausea: gastrointestinal upset.\n- Anxiety: heightened sympathetic activity.\n\nSerious or Rare Side Effects:\n- Myocardial ischemia: excessive coronary vasoconstriction.\n- Severe hypertension: risk of cerebrovascular events.\n- Tissue necrosis at infusion site: extravasation injury.\n- Life‑threatening arrhythmias: ventricular tachycardia/fibrillation.\n- Pulmonary edema: fluid overload with high cardiac output.

Careful monitoring is required when administering Mykronor to avoid complications.\n\nMonitor blood pressure: adjust infusion to maintain target MAP.\nAssess cardiac function: avoid in uncontrolled tachyarrhythmias.\nUse with caution in myocardial ischemia: risk of worsening ischemia.\nAvoid extravasation: ensure secure intravenous access.\nStore at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Noradrenaline Tartrate can interact with several drug classes, altering its pressor effect or safety profile.\n\nMajor Interactions (Avoid):\n- Monoamine oxidase inhibitors: may precipitate hypertensive crisis.\n- Tricyclic antidepressants: additive vasoconstrictive effect.\n- Beta‑blockers: can blunt desired increase in cardiac output.\n\nModerate Interactions (Monitor Closely):\n- Calcium channel blockers: may enhance hypotensive episodes if noradrenaline is withdrawn.\n- Other vasopressors: risk of excessive vasoconstriction when combined.